TBXAS1: Thromboxane-A synthase
Catalyzes the conversion of prostaglandin H2 (PGH2) to thromboxane A2 (TXA2), a potent inducer of blood vessel constriction and platelet aggregation.
- Drugs that act on it: 3
- Approved: 2
- In phases 1 to 3: 1
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on TBXAS1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 3
| Ozagrel | Approved | Kissei Pharmaceutical Co., Ltd. | Small molecule | Inhibitor | 0 |
| Picotamide | Approved | — | Small molecule | Inhibitor | 0 |
| Terbogrel | Phase 2 | Boehringer Ingelheim Pharmaceuticals | Small molecule | Inhibitor | 0 |
- Ghosal hematodiaphyseal dysplasia0.79
- Platelet-type bleeding disorder 140.55
- Anemia (phenotype)0.37
- Bone disorder0.37
- Recurrent thrombophlebitis0.37
- Dry eye syndrome0.36
- Stroke disorder0.33
- Alcohol drinking0.32
- Tricuspid valve disorder0.32
- Precordial pain0.32
- Parasitic infectious disease0.27
- Angina pectoris0.27
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1835, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P24557, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets